March 30, 2021 10:20 AM EDTUpdated 02:34 PM
News Briefing

For­ma sees da­ta 'sup­port­ing' sick­le cell ther­a­py dos­ing lev­els; Lian­Bio teams with Tar­sus for eye ir­ri­ta­tion in Chi­na

Max Gelman

Senior Editor

Look­ing to make a splash in sick­le cell, For­ma Ther­a­peu­tics pre­sent­ed new da­ta they hope can im­prove their shot at an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times